Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Pharmacokinetics of nilotinib in pediatric patients with Philadelphia Chromosome-positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia

Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia
Hijiya N et al. Clin Cancer Res, February 2020 - open access publication

Link to full abstract

 

 

 

Implementation of a physiologically based pharmacokinetic modeling approach to guide optimal dosing regimes for imatinib and potential drug interactions in paediatrics

Implementation of a physiologically based pharmacokinetic modeling approach to guide optimal dosing regimes for imatinib and potential drug interactions in paediatrics
Adiwidaja J et al. Front Pharmacol, January 2020 – open access publication

Link to full abstract

 

 

 

Discontinuation of tyrosine kinase inhibitor in a child with chronic myeloid leukemia

Discontinuation of imatinib in a child with chronic myeloid leukemia
Jeyaram P et al. Pediatr Hematol Oncol, January 2020
 

Link to full abstract

 

Outcomes of allogeneic hematopoietic cell transplantion for childhood chronic myeloid leukemia: Single-center experience

Outcomes of allogenic hematopoietic cell transplantation for childhood chronic myeloid leukemia: Single-center experience
Hafez HA et al. Pediatr Transplant, February 2020

Link to full abstract

 

 

 

Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukemia in children

Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukemia in children
Knöfler R et al. Br J Haematol, October 2019 (epub ahead of print)
 

Link to full abstract

 

  1. Acquired neuro-secretory defect in growth hormone secretion due to imatinib mesylate and the efficacy of growth hormone therapy in children with chronic myeloid leukemia
  2. Discontinuation of tyrosine kinase inhibitor in children with chronic myeloid leukemia (JPLSG STKI-14 study)
  3. Successful haploidentical stem cell transplant with post-transplant cyclophosphamide for isolated central nervous system blast crisis in a child with chronic myeloid leukemia
  4. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia (Hijiya N et al. Blood, September 2019)